These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 30739795

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.
    Vaccine; 2014 Nov 12; 32(48):6499-504. PubMed ID: 25258101
    [Abstract] [Full Text] [Related]

  • 5. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA.
    Clin Infect Dis; 2021 Sep 07; 73(5):816-823. PubMed ID: 33605977
    [Abstract] [Full Text] [Related]

  • 6. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS, Bizjajeva S, Heijnen E, Oberye J.
    Int J Infect Dis; 2019 Aug 07; 85S():S18-S25. PubMed ID: 31051279
    [Abstract] [Full Text] [Related]

  • 7. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney KK.
    JAMA Netw Open; 2020 May 01; 3(5):e204079. PubMed ID: 32369177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M.
    Vaccine; 2015 Nov 27; 33(48):6684-8. PubMed ID: 26518405
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
    van Aalst R, Gravenstein S, Mor V, Mahmud SM, Wilschut J, Postma M, Chit A.
    Vaccine; 2020 Jan 10; 38(2):372-379. PubMed ID: 31606249
    [Abstract] [Full Text] [Related]

  • 18. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P, Arana J, Pilishvili T, Lewis P, Moro PL, Cano M.
    Vaccine; 2016 Dec 07; 34(50):6330-6334. PubMed ID: 27836437
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.